Peil Biomedical Subsidiary Receives NMPA Approval for Phase I Clinical Trial of RA Drug PP011 in China

1. Date of Occurrence: 2026/06/02 2. New Drug Name or Code: PP011 3. Purpose: Rheumatoid Arthritis (RA) 4. Planned Development Stages: Phase I clinical trial, Phase II clinical trial, Phase III clinical trial, and new drug registration review. 5. Current Development Phase: The company has received approval from China's National Medical Products Administration (NMPA) to conduct Phase I clinical trials for healthy volunteers. 6. Next Development Stage: Expected to complete Phase I clinical trial in Q1 2027. 7. Market Condition: The global rheumatoid arthritis (RA) market is in a growth phase. According to IMARC Group, the market scale is expected to reach $35.4 billion by 2035. Current treatments mainly consist of biologics, which are injectable. Oral drugs offer a solution to the inconvenience of injections, although existing oral options have side effects.